AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...
J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment
The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...
Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth
Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...
Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for...
Uni-Bio Science Group Wins NMPA Nod for Generic Forteo Injection for Osteoporosis
Hong Kong-listed biopharmaceutical company Uni-Bio Science Group Ltd (HKG: 0690) has announced that it has...
Endoso Life Raises Over $14 Million in Series A to Expand Endoscope Product Lines
Endoso Life, a developer of high-end medical endoscope systems headquartered in Hangzhou, has reportedly secured...
Convalife Pharmaceuticals and Divamics Inc. Join Forces to Advance Drug Discovery with AI
Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing...
Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...
HighTide Therapeutics to Extend NASH Treatment Reach into Hebei Province
HighTide Therapeutics Inc. (HKG: 2511), a China-based non-alcoholic steatohepatitis (NASH) drug developer that recently made...
AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics
Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into...
InnoCare Makes Minjuvi Combo Treatment Available to Patients in China’s GBA
InnoCare (HKG: 9969; SHA: 688428), a China-based biopharmaceutical company, has announced that the combination treatment...
Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development
The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed...
Lee’s Pharmaceutical to Develop Windtree’s Cardiovascular Drugs in Greater China
Lee’s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics...
BeiGene Submits Additional Application for Tislelizumab in NSCLC in China
BeiGene (NASDAQ: BGNE) has announced the submission of a supplementary Biologic License Application in China...
Abbott Initiates Clinical Study for Volt PFA System in Australia for Cardiac Arrhythmias
Abbott (NYSE: ABT) has announced that the first patients have been treated with its Volt...
AbbVie Grants Enigma Biomedical Group Rights to Next-Generation PET Imaging Biomarkers
AbbVie (NYSE: ABBV), a leading pharmaceutical company in the US, has licensed to Canada-based Enigma...
Sichuan Health Commission Issues Directive to Strengthen Oversight of External Prescriptions
The Health Commission of Sichuan Province has issued a notification aimed at enhancing the management...
Shaanxi Panlong Pharmaceutical Partners with Xi’an Medical University for Multifaceted Collaboration
Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864), a leading pharmaceutical company based in China,...
Tasly Pharmaceuticals Gets NMPA Go-Ahead for Clinical Trial of Stem Cell Therapy in Heart Failure
Tasly Pharmaceuticals (SHA: 600535), a leading pharmaceutical company in China, has announced that it has...
Sinocelltech Granted NMPA Approval for Phase I Clinical Trial in Hematological Malignancies
Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has announced that it...